Drug Research
Vesselon Acquires FDA-Approved Lipid Microsphere Drug Imagent For Therapeutic Platform
Vesselon, an oncology therapeutics company, announced the acquisition of an FDA-approved drug Imagent®. Vesselon will use Imagent to create novel therapeutic complexes in four classes of cancer drugs: cytokines, oncolytic viruses, monoclonal antibodies, and nucleic acid constructs.
Vesselon incorporates Imagent...
Drug Research
FDA Approves Daiichi Sankyos TURALIO pexidartinib for the Treatment of Select Patients with TGCT a Rare and Debilitating Tumor
Daiichi Sankyo Company, Limited announced that the U.S. FDA approved TURALIO™ (pexidartinib) as the first and only treatment for adult patients with symptomatic TGCT associated with severe morbidity or functional limitations and not amenable to improvement with surgery.
TGCT is...
Drug Research
LexaGene Approved by CDC and FDA Antibiotic Resistance Isolate Bank to Receive Samples
LexaGene Holdings, Inc, a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers, announced that it has been recognized by the Centers for Disease Control and Prevention (CDC) and the FDA Antibiotic Resistance (AR) Isolate...
Articles
Drug-Eluting Devices: Delivering on Drug Delivery’s Combined Potential
Implantable drug-eluting devices (DEDs) have come a long way since 1938, when Finland approved a subcutaneously administered birth control device delivering levonorgestrel.
Over their development history, the therapeutic performance and value of DEDs has evolved significantly, and recent innovation has...
Articles
A Powerful Pairing: Academia-Industry Collaborations for Pharmaceutical Innovation
Innovation is unarguably the essence of pharmaceutical discovery and development. Industry and academia have been working together for decades, but historically relationships did not extend far beyond the traditional exchange of funding and research. There is a risk, however,...
Drug Research
New state of the art cleanroom completed by WHP for ADC bio
Production of new anti-cancer drugs at ADC Bio’s North Wales manufacturing plant has been boosted following completion of a new cleanroom facility, designed and built by WHP.
This forms a key part of ADC Bio’s construction of a new bioconjugation...
Drug Research
Pathogen engineered to self destruct underlies cancer vaccine platform
A team of investigators has developed a cancer vaccine technology using live, attenuated pathogens as vectors. A feature of the vaccine causes these bacteria to self-destruct once they've done their job, making it safe for use in humans. The...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
